Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Bristol Myers Squibb

Main (gene editing) focus: Next-generation cellular therapies

Company stage: Commercial

Diseases (gene editing): Acute myeloid leukaemia (AML), multiple myeloma (MM), other haematological and solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:BMY)

Location: New York City, New York, USA



Gene editing partnerships: Century Therapeutics

Bristol Myers Squibb (BMS) is a big pharma company developing drugs within many different disease areas. The company is engaged in the gene-editing space through its collaboration with Century Therapeutics, which is an early stage company developing gene-edited iPSC-derived cellular therapies. Together, the two companies will develop programmes with the intent to treat acute myeloid leukaemia and multiple myeloma.


HashtagBristol Myers Squibb

Company: Bristol Myers Squibb
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine